Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A phase I study of cytembena

S Frytak, C G Moertel, A J Schutt

    Cancer
    |March 1, 1976
    PubMed
    Summary

    Cytembena (Cytembena) toxicity was dose-related, with an acceptable regimen of 400 mg/m2/day for 5 days. Side effects included nausea, vomiting, and transient renal changes, with an "autonomic-storm" at higher doses.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma.

    Cancer·2001
    Same author

    PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma.

    Investigational new drugs·1999
    Same author

    Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group.

    International journal of radiation oncology, biology, physics·1998
    Same author

    Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group.

    Annals of internal medicine·1998
    Same author

    Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer.

    Cancer chemotherapy and pharmacology·1998
    Same author

    Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1998

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Cytembena is an investigational chemotherapeutic agent.
    • Understanding its toxicity profile is crucial for safe clinical use.

    Purpose of the Study:

    • To determine the toxicity patterns of Cytembena.
    • To establish a safe and tolerable dosage for intravenous administration in a 5-day intensive course.

    Main Methods:

    • A dose-escalation study was conducted in 22 patients.
    • Patients received progressively increasing doses of Cytembena.
    • Toxicity was monitored, and an acceptable dosage was determined.

    Main Results:

    • Toxicity was dose-dependent, observed at 300 mg/m2 and intolerable at 475 mg/m2.
    • Common toxicities included nausea, vomiting, arm pain, and transient renal impairment.
    • An "autonomic-storm" phenomenon occurred at higher doses, characterized by hypertension, tachycardia, and EKG changes.
    • No permanent organ damage was noted.

    Conclusions:

    • An acceptable treatment regimen is 400 mg/m2/day for 5 days, potentially divided into two doses to reduce discomfort.
    • Contraindications include coronary artery disease and impaired renal function; caution is advised for liver impairment.
    • Two patients with advanced cancer showed objective responses, warranting further Phase II studies for antineoplastic activity.

    Related Experiment Videos